Cas:1142210-81-8 5-tert-butyl 3-ethyl 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)-dicarboxylate manufacturer & supplier

Chemical Name:5-tert-butyl 3-ethyl 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)-dicarboxylate

CAS.NO:1142210-81-8

Synonyms:5-tert-butyl 3-ethyl 1-methyl-4H,6H,7H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate;5-tert-butyl 3-ethyl 1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate

Molecular Formula:C₁₅H₂₃N₃O₄

Molecular Weight:309.36100

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:73.66000

Exact Mass:309.16900

LogP:1.82790

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-tert-butyl 3-ethyl 1-methyl-4H,6H,7H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-tert-butyl 3-ethyl 1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-tert-butyl 3-ethyl 1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate Use and application,5-tert-butyl 3-ethyl 1-methyl-4H,6H,7H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate technical grade,usp/ep/jp grade.

Related News: The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 5-tert-butyl 3-ethyl 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)-dicarboxylate manufacturer Active pharmaceutical ingredients directly impact disease. 5-tert-butyl 3-ethyl 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)-dicarboxylate supplier In order to find answers to these questions, our staff in the development department set about conducting a series of experiments. 5-tert-butyl 3-ethyl 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)-dicarboxylate vendor Active pharmaceutical ingredients directly impact disease. 5-tert-butyl 3-ethyl 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)-dicarboxylate factory The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful.